Senti Biosciences Announces New Employment Inducement Grants
Senti Biosciences (Nasdaq: SNTI) announced that on Dec 12, 2025 its board granted inducement stock options to one new employee to purchase 13,680 shares at an exercise price of $1.31 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI) announced that on Dec 12, 2025 its board granted inducement stock options to one new employee to purchase 13,680 shares at an exercise price of $1.31 per share. The awards were granted under the company's Amended and Restated 2022 Inducement Equity Plan and were described as material inducements under Nasdaq Listing Rule 5635(c)(4). The Plan was initially adopted by the board on Aug 5, 2022. No additional financial guidance, vesting schedule, or dilutive impact was disclosed in the announcement.
Details
News Market Reaction – SNTI
On Dec 19, the first trading day after this news, SNTI closed 2.56% above the previous close.
Data tracked by StockTitan Argus for the Dec 19 session.
Key Figures
- Inducement options granted
- 13,680 shares
- Stock options to one new employee effective December 12, 2025
- Option exercise price
- $1.31 per share
- Exercise price for inducement stock options
- Plan adoption date
- August 5, 2022
- Amended and Restated 2022 Inducement Equity Plan board adoption
- NASDAQ rule
- Rule 5635(c)(4)
- Basis for inducement grant exemption from shareholder approval
Historical Context
-
FDA RMAT designation for SENTI-202 in R/R AML patients.
-
Updated Phase 1 SENTI-202 data with strong ORR and CR/CRh rates.
-
Announcement of ASH webcast to discuss SENTI-202 clinical data.
-
Q3 2025 loss of $18.1M and low cash balance disclosure.
-
Announcement of updated SENTI-202 ASH presentations with positive signals.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that effective December 12, 2025 Senti Bio’s Board of Directors granted to one new employee stock options to purchase an aggregate of 13,680 shares of the Company’s common stock with a per share exercise price of
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was initially adopted by the Company’s board of directors on August 5, 2022.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Bio
For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on X (formerly Twitter) (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.